HCC Clinical Trials

151 clinical trials for HCC across international registries, including 28 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• FOG-001 in Locally Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• Multi-analyte Blood Test Clinical Trial — RECRUITING
• CEUS vs. AMRI for HCC Detection in Patients With Indeterminate Liver Nodules — RECRUITING · NA
• Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma — RECRUITING · PHASE2
• Y-90 Treatment Response Using Transarterial Radioembolization — RECRUITING · PHASE2
• Effect of the HCC Liver-Link Intervention — RECRUITING · NA
• SBRT in HCC With Oligoprogression on First-line Immunotherapy — RECRUITING · NA
• A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC — RECRUITING · PHASE2
• SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis — RECRUITING · PHASE2
• REGULUS: MRI-guided Adaptive SABR for Liver Cancers — RECRUITING · PHASE2
• A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC — RECRUITING · PHASE2
• HOPE Against Cancer Recurrence in HCC — RECRUITING · PHASE4
• Understanding Gene ENvironment Interaction in ALcohol-related Hepatocellular Carcinoma — RECRUITING · NA
• Evaluation of Risk of hEpatocellular Carcinoma — RECRUITING · NA
• Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy for Unresectable Intermediate-to-Advanced Hepatocellular Carcinoma — RECRUITING · PHASE2
• Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model — RECRUITING · PHASE2
• A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk — RECRUITING · PHASE4
• A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer. — RECRUITING · PHASE2
• Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC — RECRUITING · PHASE2
• Phase I Study of OriC902 in Treatment of Advanced HCC — RECRUITING · PHASE1
• A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma — RECRUITING · PHASE1
• A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors — RECRUITING · PHASE1
• A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related — RECRUITING · PHASE1
• CT011 Autologous CAR-T Cells in Patients With Hepatocellular Carcinoma at Risk of Recurrence After Surgical Resection — RECRUITING · PHASE1
• Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC. — RECRUITING · PHASE4
• Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma — RECRUITING · PHASE4
• TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma — RECRUITING · PHASE2
• HCC Surveillance: Comparison of Abbreviated Non-contrast MRI and Ultrasound Surveillance in Cirrhotic Patients With Suboptimal Ultrasound Visualisation — RECRUITING · NA
• Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC — NOT_YET_RECRUITING · PHASE2
• Partial Immune-boost TACE in unrEseCTable HCC Patients Under Systemic Treatment — NOT_YET_RECRUITING · PHASE2
• A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• Optimizing Y90 Therapy for Radiation Lobectomy — ACTIVE_NOT_RECRUITING
• A Phase 2b Study of Modified Vaccinia Virus to Treat Patients Advanced Liver Cancer Who Failed Sorafenib — COMPLETED · PHASE2
• Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC — ACTIVE_NOT_RECRUITING · PHASE2
• CXD101 in Immunotherapy-related Liver Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• IL1RAP-targeting Chimeric Antigen Receptor T Cells in the Treatment of Relapsed/Refractory Hepatocellular Carcinoma — ACTIVE_NOT_RECRUITING · PHASE1
• GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC — ACTIVE_NOT_RECRUITING · PHASE1
• Pembrolizumab in Hepatocellular Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• Cabozantinib in Hepatocellular Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• Adjuvant Anti-PD-1 Therapy in Resected Hepatocellular Carcinoma — NOT_YET_RECRUITING
• Preliminary Evaluation of Clinical Application of SPECT Imaging Targeting GPC3 — NOT_YET_RECRUITING · NA
• Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC — NOT_YET_RECRUITING · NA
• Sintilimab Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Resectable Hepatocellular — NOT_YET_RECRUITING · PHASE2
• TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension — NOT_YET_RECRUITING · PHASE2
• ICIs With and Without MWA in Advanced Hepatocellular Carcinoma — COMPLETED
• TACE Versus HAIC, Combined With PD-1 Inhibitors and Lenvatinib for Unresectable Hepatocellular Carcinoma — NOT_YET_RECRUITING
• Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• A Clinical Study Evaluating HAIC Combined With Iparomlimab and Tuvonralimab Injection Plus Bevacizumab in Patients With Initially Potentially Resectable Hepatocellular Carcinoma (ITBHaic Study) — NOT_YET_RECRUITING · PHASE2
• A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer — COMPLETED · PHASE2
• A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence — ACTIVE_NOT_RECRUITING · NA

Refine this search